KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Wildtype P53 Tumors with Superior Potency and Differentiated Biological Activity Compared to Small Molecule Inhibitors (SMI)
Cancer Research（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined